News | Endoscopes | December 23, 2019

Boston Scientific Receives FDA Clearance For World's First Single-use Duodenoscope

U.S. Food and Drug Administration granted EXALT Model D single-use duodenoscope breakthrough device designation, expediting physicians' access to a new, sterile device for each patient

U.S. Food and Drug Administration granted EXALT Model D single-use duodenoscope breakthrough device designation, expediting physicians' access to a new, sterile device for each patient

December 23, 2019 — Boston Scientific Corporation announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the EXALT Model D Single-Use Duodenoscope for use in endoscopic retrograde cholangiopancreatography (ERCP) procedures. The EXALT Model D Duodenoscope is the first and only FDA cleared single-use (disposable) duodenoscope on the market and was granted Breakthrough Device Designation from the FDA to ensure patients and healthcare providers have timely access to this device.

This groundbreaking device has been developed as an alternative to reusable duodenoscopes, eliminating the need for duodenoscope reprocessing and repairs, and allowing physicians to use a new, sterile device for every procedure. The EXALT Model D Duodenoscope builds on the familiar design of standard reusable duodenoscopes so that physicians experience a minimal learning curve when adopting this technology.

Every year, more than 1.5 million ERCPs are performed worldwide using duodenoscopes to diagnose and treat various pancreatic and biliary conditions.1,2 

Reusable duodenoscopes are put through a rigorous disinfection process between uses in different patients and the vast majority of procedures with these devices are carried out safely and effectively; however, there have been a small number of cases in which infections have been transmitted between patients via contaminated devices, despite adherence to established protocols. As a result, the FDA has been working with duodenoscope manufacturers, medical societies, physicians and other stakeholders to address this concern. The FDA recently issued a recommendation that healthcare providers transition to duodenoscopes with disposable components or fully disposable devices, when they are available, and held an advisory committee meeting to discuss this process and other issues related to reducing infection transmission by reusable duodenoscopes.

"The EXALT Model D Duodenoscope was developed to support clinicians in their mission to deliver the highest quality patient care," said Art Butcher, senior vice president and president, endoscopy, Boston Scientific. "As a leading industry partner committed to advancing the care of pancreaticobiliary diseases for over 30 years, helping to ensure the integrity of ERCP is inherent in our mission to advance science for life and transform patient lives. This device, which was granted Breakthrough Device Designation by the FDA, builds on our legacy of delivering meaningful innovation that improves clinical outcomes."

The FDA Breakthrough Devices Program is intended to help patients receive timely access to breakthrough technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions.

Boston Scientific voluntarily conducted a consecutive case series of the EXALT Model D Duodenoscope and found that expert endoscopists were able to complete ERCPs across a wide range of complexity using the single-use duodenoscope.3

"With the EXALT Model D Duodenoscope, I can perform the same high-quality ERCP procedure with the added benefit of using a brand-new sterile device for each patient," said Raman Muthusamy, M.D., medical director of endoscopy, professor of clinical medicine, David Geffen School of Medicine at UCLA. "I believe the development of this device is a significant advancement in the evolution of endoscopy."

The company plans to commence a limited market release of the device in the U.S. during the first quarter of 2020.

For more information: www.bostonscientific.com/EXALT

Related Content

Emagine Solutions Technology's VistaScan portable ultrasound enables doctors to enhance patient care. Clinicians can diagnose in moments, saving time and lives at a fraction of the cost of a cart ultrasound machine

Emagine Solutions Technology's VistaScan portable ultrasound enables doctors to enhance patient care. Clinicians can diagnose in moments, saving time and lives at a fraction of the cost of a cart ultrasound machine. Photo credit: Tech Parks Arizona

News | Ultrasound Imaging | February 27, 2020
February 27, 2020 — Emagine Solutions Technology, an award-winnin
In a study of more than 1,000 patients published in the journal Radiology, chest CT outperformed lab testing in the diagnosis of 2019 novel coronavirus disease (COVID-19) #COVID19 #COVID-2019 #2019nCoV

Chest CT images of a 29-year-old man with fever for 6 days. RT-PCR assay for the SARS-CoV-2 using a swab sample was performed on Feb. 5, 2020, with a positive result. (A column) Normal chest CT with axial and coronal planes was obtained at the onset. (B column) Chest CT with axial and coronal planes shows minimal ground-glass opacities in the bilateral lower lung lobes (yellow arrows). (C column) Chest CT with axial and coronal planes shows increased ground-glass opacities (yellow arrowheads). (D column) Chest CT with axial and coronal planes shows the progression of pneumonia with mixed ground-glass opacities and linear opacities in the subpleural area. (E column) Chest CT with axial and coronal planes shows the absorption of both ground-glass opacities and organizing pneumonia. Image courtesy of Radiology

News | Computed Tomography (CT) | February 26, 2020 | Melinda Taschetta-Millane and Dave Fornell
February 26, 2020 — In a study of m
 over the course of a week and a half #coronavirus #COVID19 #COVID-2019 #2019nCoV

29-year old male with unknown exposure history, presenting with fever and cough, ultimately requiring intensive care unit admission. (a) Axial thin-section non-contrast CT scan shows diffuse bilateral confluent and patchy ground-glass (solid arrows) and consolidative (dashed arrows) pulmonary opacities. (b) The disease in the right middle and lower lobes has a striking peripheral distribution (arrow). Image courtesy of Radiology 

News | Computed Tomography (CT) | February 26, 2020
February 26, 2020 — Mount Sinai Health System physicians—the
Images in a 41-year-old woman who presented with fever and positive polymerase chain reaction assay for the 2019 novel coronavirus (2019-nCoV) #coronavirus #nCoV2019 #2019nCoV #COVID19

Images in a 41-year-old woman who presented with fever and positive polymerase chain reaction assay for the 2019 novel coronavirus (2019-nCoV). Three representative axial thin-section chest CT images show multifocal ground glass opacities without consolidation. Three-dimensional volume-rendered reconstruction shows the distribution of the ground-glass opacities (arrows). Image courtesy of the Radiological Society of North America (RSNA)

News | Radiology Imaging | February 25, 2020
February 24, 2020 — The U.S.
Carestream’s state-of-the-art OnSight 3D Extremity System
News | Computed Tomography (CT) | February 25, 2020
February 25, 2020 — Carestream’s state-of-the-art...
An axial CT image obtained without intravenous contrast in a 36‐year‐old male (Panel A) shows bilateral ground‐glass opacities in the upper lobes with a rounded morphology (arrows). #coronavirus #nCoV2019 #2019nCoV #COVID19

An axial CT image obtained without intravenous contrast in a 36‐year‐old male (Panel A) shows bilateral ground‐glass opacities in the upper lobes with a rounded morphology (arrows). Image courtesy of Radiology Online.

News | Computed Tomography (CT) | February 20, 2020
February 20, 2020 — In new research